Rituximab is used in patients with membranous nephropathy, depending on the dose, and the regimen consists of either once a week or once every two weeks, with the dose varying at different frequencies. Rituximab can be used in patients with primary membranous nephropathy, and treatment with rituximab alone or in combination with a calcineurin inhibitor for at least 6 months is recommended for intermediate- to high-risk patients. Treatment regimens include intravenous rituximab 375 mg/m² once a week for 4 weeks for 1 course of treatment or 1 g/dose at 2-week intervals for a total of 2 courses of treatment. After 6 months of treatment, the decision of whether to administer another injection is based on the degree of B-cell rebound, the level of anti-PLA₂R antibody, and clinical remission. Some patients may experience adverse reactions such as throat itchiness, nasal congestion, facial flushing, flu-like symptoms, and rash after rituximab injection. Precautions include using this drug with caution if you are already in an immunocompromised or deficient state prior to use, while children should use the drug with caution. Patients with membranous nephropathy injected with rituximab should strictly consult with their physicians and under the guidance of their physicians, and should not use the drug without authorization or increase the course of treatment as well as the dosage of the drug without authorization.